Slides
Page 1
1 2025/26 Results PresentationProactive Healthy Longevity
Page 2
Agenda & Presenters 2 Overview – A Transformational PeriodJerry Randall, Chief Executive Officer Financial PerformanceDanny Wells, Chief Financial Officer Commercial, Marketing and Innovation ProgressKate Bache, Chief Innovation & Marketing Officer and Gervase Fernandes, Strategic Growth Director Strategic Update & OutlookJerry Randall, Chief Executive Officer
Page 3
Venture Life At a Glance Entrepreneurial TeamOmnichannel ModelPortfolio Divide Innovation EngineGrowing CategoriesStrong Brand Portfolio 60+ EmployeesAdded high-value experts across marketing, digital, operations and commercial 4 Balanced ChannelsTrusted, longstanding retail and pharmacy relationships, supported by rapidly growing online and partner channels87k Distribution Points+40% 19 Product LaunchesDuring FY2025/268 BrandsIn the areas of Women’s Intimate Health, Hormonal Health, Diabetes Management, Ear Care and Oncology Support 4 Key CategoriesTargeting categories with strong structural tailwinds and headroom for growth VLG Brands Balance Activ Lift Earol Balance Activ EarolGelclair Health & Her10.7
Page 4
A Transformational Reporting PeriodSimplified our portfolio, strengthened our balance sheet and repositioned the Group as a pure-play consumer healthcare business. Financial & Operational Highlights17.0% revenuegrowth delivered by our Power Brands18.9% EBITDA growth on LTM1 basis£3.4m Group Profit Before Tax incl. Profit from discontinued operations£4.7m returned to shareholders in the period+40% growth in distribution across UK & USchannelsMicrosoft Dynamics 365 ERP successfully implemented Successful Pivot to Pureplay StrategySimplified: vertically integrated to a scalable, asset-light platform, following divestmentsFocused: pure-play, brand-led consumer healthcare businessExpanded: entered higher-growth categories via acquisitionsScaled: US operations established post-period end – acquisition of FemiClear and CUROXEN Growth Drivers Innovation: science-backed and informed by consumer insightUSA Scale: VLG brands introduced through new US operations Distribution: expansion across retail, pharmacy and e-commerceStrong Balance Sheet: capacity for organic investment and M&A 1LTM = Last Twelve Months
Page 5
5Financial Performance
Page 6
FY2025/26 Financial Performance £50.0mRevenue+16.0% LFL £22.3mGross Profit(2024: £12.2m) £7.9mAdjusted1 EBITDA 5.8 penceAdjusted3 Diluted EPS(2024: 3.1 pence) £3.5mFree Cash Flow(2024: £3.7m) £11.5mCash (2024: Net debt £18.8m) 1Adjusted EBITDA and EPS is EBITDA before deduction of exceptional items and share based payments +19% on LTM2 basis 2 LTM = Last Twelve Months versus December Interim Results
Page 7
Strong Revenue Performance Across Our Power BrandsFinancial performance 7.5 8.8 9.1 9.4 10 11.4 6 5.8 6.6 5.9 8.5 8.5 2.8 2 2.9 £0 .0£1 0.0£2 0.0£3 0.0£4 0.0£5 0.0 31 -D ec-24 31 -D ec-25 31 -M ay-2612 mths12 mths12 Emth s Revenue By Therapy Area Women’s HealthEnergy ManagementEar CareHormonal HealthOnc ology SupportOth er •Proforma1 revenue growth from the Power Brands has been building over the period:•Power Brands grew +14.9% for the 12 months to Dec’25•Growth from both owned brands and international partners •Diverse group of therapy areas all growing well•Non-Core Oncology Support range delivering stable revenue and margin with longstanding customers Power Brands grew 17.0% over the seventeen-month period and are gaining momentum:•H1-25 growth +11.4%•H2-25 growth +17.9%•5mths to May 2026 + 20.7% £39.9 £46.7 £3.2 £3.3 31 -M ay -25 31 -M ay -26 17 mth s17 mth s 17 Month Revenue Performance Power Brand sOther Brands £28.8 £33.1 £35.6 £2.9 £2.1 £3.0 31 -De c-24 31 -De c-25 31 -M ay -2612 mth s12 mth s12 Emt hs 12 Month Rolling Revenue Performance Power Brand sOther Brands 1Proforma basis includes acquisitions as if they had been in place for all of the comparative period
Page 8
Gross Margin Improvement Through Transformation ActivitiesFinancial performance 39.6%40.2%41.6%45.8%45.0%45.2%44.6%49.7% 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% FY2 1FY2 2FY2 3FY2 4CY25LT M May26*FY2 5/27FY2 6/27FY2 1FY2 2FY2 3FY2 4CY25LT M May26*FY2 5/27FY2 6/27 FY25/26 Gross Margin reduced slightly versus FY24 but has improved materially compared to pre-divestment levels, reflecting Power Brand focus FY25/26 product mix adversely impacted by ordering patterns with a key UK customer in the final quarter of the PeriodSuccessfully implemented price increases across Power Brands during the Period, largely offsetting general inflationary cost pressures FY25/26 Gross margin guidance for FY26/27 step-up driven by accretive impact of FemiClear acquisition post period-end and innovation launches
Page 9
LTM1 Adjusted EBITDA gaining momentum ahead of FemiClear and CUROXEN acquisition post period-end Financial performance £6,600k£8,962k £4,895k£6,174k£5,951k£7,084k£7,853k £11,574k 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 FY2 1FY2 2FY2 3FY2 4CY25LT M May26*FY2 5/27FY2 6/27FY2 1FY2 2FY2 3FY2 4CY25LT M May26*FY2 5/27FY2 6/27FY25/26 1 LTM = Last Twelve Months rolling basis Operating cost base temporarily lost leverage following divestmentsOperating costs increased reflecting full year impact of acquisition, increased A&P and strengthening of organisational capability Restructuring activities undertaken during the Period to drive focus on delivering the simplified business modelAcquisition of FemiClear on 2 June 2026 driving full year impact of EBITDA inclusion into 2026/27
Page 10
Cash Flow and Net Cash MovementFinancial performance £4.3 £56.1↑↓(£7.3) ↓(£22.2) £7.9↑↓(£5.3) £2.3↑↓(£0.4)↓(£0.6)↓(£1.0)↓(£4.7) ↓(£17.1)↓(£0.4)£11.5 (10)0102030405060 Opening Cash Balance Proceeds fromDivestment of AssetsHe ld for SaleCash expendaturerelating to DiscontinuedOperations Net RC F R epayment EBITDA fromContinueing Operations Exceptional Costs Working Capital Paid Interest Tax Paid Defer red ContingentConsideration rel atingto Health & HerSpend relating toShare Buyback SchemeTransfer of EscrowFunds relating toFemiclear Acquisition Other Closing Cash BalanceDiscontinued OperationsContinuing OperationsInvestment Activities Cash balance remains strong after investment in FemiClear c.£56m cash proceeds from divestments, used to repay borrowings, invest in the ERP implementation and fund the share buyback programme Cash transferred at period-end for acquisition of FemiClear and CUROXEN completed on 2 June 2025 Operating cash conversion of 56.2% and Free Cash Flow conversion of 44.7% were significantly impacted by cash exceptional costs
Page 11
11 Commercial, Marketing and Innovation Progress
Page 12
Hormonal Health +28%Revenue61k(+6%)Dist. Points Long-Term Growth Expanding category leadership across into Men’s Health with Health & Him Uniquely positioned to provide products for every stage of the hormonal journey Significant international growth opportunity especially in US Proven MomentumUK’s No.1 Menopause Brand (Circana Value Sales Data) Cost Price increase successfully implemented to align with rising cost pressures Distribution increases (+6%) across key strategic customers inUK, USA, and EU New marketing campaign ‘for every stage of you’ driving momentum across life-stages Near-Term Growth Drivers Increased focus on US retail growth over the next 12 months both offline and onlineNew range of longevity supplements to enter into fast-growing need-stateInnovation into key risk areas associated with dropping hormonesMarketing to influence key educational moments including TikTok, podcasts and HCPsStrong innovation pipeline driven by proprietary data and university partnerships ******** *** Innovation launched in latest 17M stretched the brands into new life-stages (12 new products*) * Excellent growth in the recently launched Health & Him range (+273%)
Page 13
Women's Health+15%Revenue17k(+5%)Dist. Points Long-Term Growth Category leadership with deep insight from proprietary data and university partnerships UK’s No.1 Bacterial Vaginosis Brand (Circana Value Sales Data) Significant innovation growth opportunity into breakthrough need-states and infections Proven MomentumRetail distribution increases across UK High Street chains (+5%)First ever ATL campaign targeting large Bacterial Vaginosis education opportunityCost price increases and updated promotion strategy driving improved profitability Near-Term Growth Drivers Two new UK retailers launching the Balance Activ range in 2026/7Innovation expansion and continued roll out of Dual Action and Test KitsNew medical device launch into Intimate Odour to support consumer’s shopper journeyBrand expansion into Balance Activ for Men to enter significant white spaceNew HCP campaign educating on the benefits of using of Lactic Acid alongside antibiotics for BV Unique positioning in the category as the only brand to own and combine natural credentials with clinical proof Innovation launched to support confusion about symptoms symptoms (Dual Action – Thrush & BV and Vaginal Test Kit*) International partner range extensions with Cooper and Bayer ** Partner BrandsPartner BrandsBalance Activ
Page 14
Energy Management+16%Revenue8kDist. Points Long-Term Growth UK’s No.1 Glucose Shot (Circana Value Sales Data) NICE recommended for T1D hypo management and NHS first line treatment Significant opportunity for penetration gains vs. dietary sugars Proven MomentumExcellent growth in online sales (+27.1%) and pharmacy channel (+10.9%)Expanded Pharmacy footprint with more pharmacy chain stores (+24% dist. pts) Near-Term Growth Drivers USA expansion into retail presenting a large opportunity for incremental growthAccelerating UK pharmacy growth nationally by expanding highly effective field sales teamContinued roll out of Gels innovation across UK and IRE retail – capitalising on early traction Continued HCP engagement campaign educating on the benefits of glucose vs. dietary sugars More than 70% of sales driven by Healthcare Professional recommendation or prescriptionNew Lift gels launched online with initial sales exceeding expectations Leveraging new in-house digital team to build online growth and subscriptions * * Marketing activities to HCPs driving high awareness of the brand amongst T1DsNew paper-roll chews and breakthrough night-time innovation launchesStrong potential for geographical expansion using UK credentials
Page 15
Ear Care+7.9%Revenue7.4k(+40%)Dist. Points Long-Term Growth Established ear-care brand with a clinically proven proposition No.1 recommended by audiologists (93% of ear care specialists*) Unique propositions for the whole family and need-states like swimmer’s ear Proven MomentumRetail Distribution increases across UK High Street in 2k+ additional storesNew radio campaign has driven brand awareness and education about wax build up and swimmer’s earUsage & proposition extension for Earol SWIM to also support Shower & Bath occasion Near-Term Growth Drivers New packaging look and feel will improve standout and claims at shelf International expansion opportunities expected with key international partner Proven instore support strategies identified to support retail growth over next 12 months International partner relationship which is strengthening sales in Europe ** Partner BrandEarol Earol Significant opportunity for geographical expansion via established international partners Increased engagement with Pharmacists and Audiologists will drive recommendation across existing and new retailers *Source: 136 participants (Audiologists and Ear Care Specialists) interviewed via an online survey on the use of Earol, prior to ear wax removal and prophylactically.
Page 16
Vaginal Health+30%Revenue74k(+69%)Dist. Points Long-Term Growth Proprietary, patented, clinically proven formulas protected by 4 patentsExceptional momentum and growth with a strong point of difference vs. medicated mainstream products Proven MomentumStep-changing distribution increases driven by increased distribution in all major retail accounts Near-Term Growth Drivers Expanding successful optimisation of retail media networks to all strategic customers Further distribution gains in large national and regional retailersNew retailers landing with regional pharmacy and grocery launching Femiclear in stores across USA Opportunity to innovate and expand into new white space infection areaDriving visibility of brand with HCPs to encourage use alongside prescription products Natural credentials and gynecologist approval supporting premium positioning in range New innovation Lysine Wash, Infection Protection and UTI flush are performing strongly since launch Digital marketing excellence including shift to omnichannel focus, geolocation and creative cadence driving strong growth ** Leveraging VLG’s deep insights from symptom tool, H&H app and established university partnerships Promotional Effectiveness utilising digital coupon platforms to target multiple retailers Leveraging new & effective Femiclear formulations in Europe
Page 17
InnovationVLG’s unique combination of deep and varied insight with an entrepreneurial approach drives our cutting-edge innovation engine Extensions of core Stretching / Breakthrough Trends Longevity Pharmaceuticals + Nutrition Couple’s health Symptom-led self-careChronic, recurrent conditions Hormonal HealthIntimate HealthEnergy Management
Page 18
18Strategic Update & Outlook
Page 19
19 THEN TODAYVertically integratedvCapital-intensive manufacturing footprint vDevelopment, contract and manufacturing operationsvBroader portfolio, including Oral Care brands outside the future strategic focus Focused, asset-light and ready to executevOutsourced manufacturing: Lower fixed-cost and capital intensityvStreamlined portfolio: Investment focused on Power BrandsvAgile operating platform: Capabilities and cash directed to growth Building a portfolio of trusted, science-backed brands that support proactive healthy longevity, underpinned by our five strategic pillars Our transformation to a growing pure-play consumer healthcare business ACQUISITONS DIVESTMENTS 20222024202620252025Oral CareAssetsCDMOOperations Acquiring & transforming core brands with a clear runway for profitable growth Integrated digital capabilities with advanced AI & robust data to drive insights Omnichannel go to market strategy tailored to where shoppers’ shop & how they buy Number 1 Brand mindset Winning Ways of Working : Core entrepreneurial competencies 1 2 3 4 5
Page 20
Structural shifts are driving sustainable demand for proactive, preventative healthcare Ageing demographics Healthspan & performance-driven wellness Microbiome & holistic health awareness Distrust of reactive “sick-care” Destigmatisation of taboo health topics Venture Life Group | Equity Story Shell 4 Significant market powered by long-term structural tailwinds Significant and growing opportunity for trusted preventative self-care brands
Page 21
Unlocking new markets through considered, strategic M&A Venture Life Group plc £108mCategory expansion in UK Women’s Intimate Health £200mEstimated US category opportunity for other Venture Life brands £500mUS retail FemCare market entry Shared consumer needs across the UK and US create a repeatable opportunity to enter new geographies and expand into adjacent Women’s Intimate Health need states. The FemiClear acquisition opens two complementary growth platforms Synergistic UK and US Growth PlatformsUS market entryScale FemiClear and accelerate selected VLG brands Need-state expansionExtend from treatment into prevention and maintenance One acquisition expands Venture Life across markets, brands and need states. Our right to winExperienced US team and extensive retail network Patented technology and evidence-led innovation Leading authority in Women’s Intimate Health
Page 22
5 Our evolution and growth ambition Four growth levers translate our ambition into delivery, targeting white space in existing and adjacent categories FY25/26 (Actuals)£50.0mRevenue£7.9m Adjusted EBITDA FY26/27 (Guidance)£54.7mRevenue£11.6m EBITDA 2030+ (Ambition)£300m+Revenue25% EBITDA margin Powered by our growth levers: Innovation · Distribution Expansion (core + new geographies) · HCP & consumer education · Strategic M&A •Integrated Health & Her•Divested CDMO and Oral Care•Significant investment in capability •Increased marketing spend to drive growth of Power Brands •Strong brand momentum entering the year•Strong balance sheet•Completed acquisition of FemiClear, expanding US presence •Continue to target expansion of Intimate and Hormonal Health segments•Focus on US expansion•Continue to invest in innovation, talented employees and building our successful omnichannel model Our outlook
Page 23
23 DisclaimerTheinformationcontainedinthispresentation(the“Presentation”)hasbeenpreparedbyVentureLifeGroupplc(the“Company”)forinformationpurposesonly.Ithasnotbeenindependentlyverifiedanddoesnotpurporttobecomprehensive.Norepresentationorwarranty,expressorimplied,ismadeastothefairness,accuracy,completenessorcorrectnessoftheinformationoropinionscontainedinthePresentation.Tothefullestextentpermittedbylaw,neithertheCompanynoranymemberofitsgroup,noranyoftheirrespectivedirectors,officers,employees,agents,advisersorrepresentatives,acceptsanyresponsibilityorliabilityforanylossarisingfromtheuseof,orrelianceon,thePresentationoritscontents.Nothinginthisdisclaimerexcludesliabilityforfraudoranyotherliabilitythatcannotlawfullybeexcluded.Unlessotherwisestated,financialinformationinthePresentationhasbeenpreparedinaccordancewithUKadoptedIFRSasatthedateofthePresentation.ThePresentationmaycontainforward-lookingstatements,includingstatementsregardingtheCompany’splans,objectives,expectations,estimatesandfutureperformance.Suchstatementsarebasedoncurrentexpectationsandassumptionsandaresubjecttoknownandunknownrisksanduncertainties.Actualresultsmaydiffermateriallyfromthoseexpressedorimplied.Recipientsshouldnotplaceunduerelianceonforward-lookingstatements,whichspeakonlyasatthedateofthePresentation.Exceptasrequiredbylaworregulation,theCompanyundertakesnoobligationtoupdateorrevisethem.ThePresentationisdirectedonlyatpersonswhoare:(i)investmentprofessionalswithinArticle19(5)oftheFinancialServicesandMarketsAct2000(FinancialPromotion)Order2005(the“Order”);(ii)highnetworthcompanies,unincorporatedassociationsandotherpersonswithinArticle49(2)oftheOrder;or(iii)otherwisepersonstowhomitmaylawfullybecommunicated(together,“relevantpersons”).AnyinvestmentorinvestmentactivitytowhichthePresentationrelatesisavailableonlytorelevantpersonsandwillbeengagedinonlywithrelevantpersons.PersonswhoarenotrelevantpersonsshouldnotactorrelyonthePresentationoritscontents.ThePresentationdoesnotconstitute,andshouldnotbeconstruedas,anoffer,solicitationorinvitationtoacquire,disposeoforsubscribeforanysecuritiesorfinancialinstruments,nordoesitconstituteinvestmentadviceoranyrecommendation.NopartofthePresentation,northefactofitsdistribution,shouldformthebasisof,orberelieduponinconnectionwith,anycontract,commitmentorinvestmentdecision.Recipientsshouldmaketheirownindependentassessmentandobtainappropriateprofessionaladvicebeforetakinganyaction.NostatementinthePresentationisintendedtoconstituteaprofitforecastorprofitestimate.Pastperformanceisnotaguidetofutureperformance.